<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>Written Evidence to the Science and Technology Committee’s Inquiry on Blood, Tissue and Organ Screening by Terumo BCT</title></head><body><div><p style="margin:0pt"><span style="font-family:'Minion Pro'; font-size:12pt">&#xa0;</span></p><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written Evidence </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">submitted by </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Terumo BCT</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> (BTO0015)</span></p><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="color:#0d0d0d; font-family:'Times New Roman'; font-size:11pt">On behalf of Terumo BCT – </span><span style="color:#0d0d0d; font-family:'Times New Roman'; font-size:11pt">a global leader in blood component and cellular technologies. It is the only company with the unique combination of </span><span style="color:#0d0d0d; font-family:'Times New Roman'; font-size:11pt">apheresis</span><span style="color:#0d0d0d; font-family:'Times New Roman'; font-size:11pt"> collections, manual and automated whole blood processing, and pathogen reduction coupled with leading technologies in therapeutic </span><span style="color:#0d0d0d; font-family:'Times New Roman'; font-size:11pt">apheresis</span><span style="color:#0d0d0d; font-family:'Times New Roman'; font-size:11pt"> and cell processing. </span></p><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="color:#0d0d0d; font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="background-color:#ffffff; font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="color:#0d0d0d; font-family:'Times New Roman'; font-size:11pt">Terumo BCT’s goal is to make even safer, higher-quality transfusions available to more people, unlocking the potential of blood and cell therapies. It also helps to bring even more treatment options to patients through advanced blood therapies and supports researchers in developing cellular therapies that may fundamentally improve health care. </span></p><p style="background-color:#ffffff; font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="color:#0d0d0d; font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">We welcome the opportunity to answer the call to provide written evidence to the UK Parliament’s Science and Technology Committee </span><span style="font-family:'Times New Roman'; font-size:11pt">i</span><span style="font-family:'Times New Roman'; font-size:11pt">nquiry on Blood, Tissue and Organ screening</span><span style="font-family:'Times New Roman'; font-size:11pt"> and hope that it will prove useful in the further development of the safety and security of the UK blood supply.</span></p><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><h1 style="font-size:11pt; line-height:150%; margin:0pt; page-break-after:avoid; page-break-inside:avoid; text-align:justify"><span style="color:#0d0d0d; font-family:'Times New Roman'; font-size:11pt; font-weight:normal">In the light of the ongoing debate within the UK Parliamentary discussion regarding Variant Creutzfeldt-Jakob (</span><span style="color:#0d0d0d; font-family:'Times New Roman'; font-size:11pt; font-weight:normal">vCJD</span><span style="color:#0d0d0d; font-family:'Times New Roman'; font-size:11pt; font-weight:normal">) disease and the safety of blood products, particularly the fact that </span><span style="color:#0d0d0d; font-family:'Times New Roman'; font-size:11pt; font-weight:normal">more than 1 in every 2000 people could be silent carriers of the disease according to the Committee, we feel that a zero tolerance approach to blood safety or as close to zero tolerance as possible should be the UK Government’s approach to the issue in general.</span></h1><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Other threats, such as the risk to the safety and security of the UK blood supply from both known and unknown pathogens, are also important to consider in this Parliamentary discussion. </span></p><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The UK provides a good example of how a government can work with policy makers, stakeholders, business and society in combating safety threats to the national blood supply, including those from emerging pathogens, such as </span><span style="font-family:'Times New Roman'; font-size:11pt">West Nile virus (WNV), Malaria, tick-borne Encephalitis, and Dengue fever. Such cooperation can also help assist with other blood supply issues, such as boosting the </span><span style="font-family:'Times New Roman'; font-size:11pt">blood donor base amongst the Black Minority Ethnic (BME) community. </span></p><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Summary of Terumo BCT’s written evidence</span></p><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; line-height:150%; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Terumo BCT want to bring to the Committee’s attention other risks recently identified by the UK Government’s Arms-Length Bodies, such as </span><span style="font-family:'Times New Roman'; font-size:11pt">Advisory Committee on the Safety of Blood, Tissues and </span><span style="font-family:'Times New Roman'; font-size:11pt">Organs</span><span style="font-family:'Times New Roman'; font-size:11pt"> (</span><span style="font-family:'Times New Roman'; font-size:11pt">SaBTO</span><span style="font-family:'Times New Roman'; font-size:11pt">), including emerging pathogens.</span><span style="font-family:'Times New Roman'; font-size:11pt"> Indeed, as the Committee may be aware, in a </span><span style="font-family:'Times New Roman'; font-size:11pt">SaBTO</span><span style="font-family:'Times New Roman'; font-size:11pt"> meeting from March, 2012, officials discussed the threat of the West Nile virus during their meeting and its continued threat to the safety and security of the UK blood supply. The Department of Health are also aware of this threat.</span></li></ul><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; line-height:150%; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">There are other emerging threats to blood safety that are not always risk assessed and which could change the current threat landscape in the UK in this area. These threats require greater precautions to further reduce risks and the introduction of additional blood safety technology, such as pathogen reduction technology, to get as close to a zero tolerance risk approach as possible. </span></li></ul><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; line-height:150%; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Terumo BCT wishes to point out that the EU Blood Directive 2002 recommends that pathogen reduction technology should be adopted, where available, in EU Member States.</span></li></ul><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; line-height:150%; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Lastly, Terumo BCT believes that in order for the UK Government and its scientific advisory structure to be sufficiently responsive to the threats posed by emerging diseases it is critical that blood donors and patients receiving blood transfusions are as well trained and informed of blood safety issues as they can be. </span></li></ul><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Are UK policies governing who can donate blood and blood products, tissues and organs sufficiently evidence-based? Is NHS Blood and Transplant overly restrictive about who can donate, or should greater precautions be taken to further reduce risk?</span></p><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:150%; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The UK policies governing who can donate blood and blood products, tissues and organs are good but there are greater precautions that can be taken to further reduce risks to the safety and security of the UK blood supply. </span></li></ol><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="2" type="1" style="margin:0pt; padding-left:0pt"><li style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt; line-height:150%; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">In particular, it is felt that the current four UK Blood Services operate well run and well established nationally managed blood collection programmes of non-remunerated voluntary blood donation. </span></li></ol><p style="background-color:#ffffff; font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="3" type="1" style="margin:0pt; padding-left:0pt"><li style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt; line-height:150%; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">These Blood Services, including NHS Blood and Transplant, supply blood to hospitals for transfusion into patients and in doing so have a legal and ethical requirement to maintain an extremely high level of blood safety, which they continue to do. We feel that these high standards also cross-over to the regulation of those </span><span style="font-family:'Times New Roman'; font-size:11pt">polices</span><span style="font-family:'Times New Roman'; font-size:11pt"> governing who can donate blood and blood products.  </span></li></ol><p style="background-color:#ffffff; font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="4" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:150%; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">However, it is important to point out that almost every medical treatment, including blood transfusion, is associated with some risk and there are emerging threats, such as known and un-known pathogens that the Blood Services need to be aware of, monitor and combat if patients are to continue to receive a high standard of blood transfusion treatment in the UK. </span></li></ol><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="5" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:150%; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">For this reason clinicians need to consider the need for any blood transfusion very carefully with their patients and, increasingly, will seek the explicit patient consent for it, following a recommendation from the </span><span style="font-family:'Times New Roman'; font-size:11pt">Advisory Committee on the Safety of Blood, Tissues and Organs (</span><span style="font-family:'Times New Roman'; font-size:11pt">SaBTO</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><a name="_ftnref1"></a><a href="#_ftn1">[1]</a><span style="font-family:'Times New Roman'; font-size:11pt">, the Government advisory body on blood safety. </span></li></ol><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="6" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:150%; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">We would like to draw to the Committee’s attention that some blood safety issues are more relevant than others when analysing blood safety and security. The risks of viral transmission by blood transfusion in the UK are exceedingly low, for example. Indeed, the last documented case of any virus transmission was in 2005, according to </span><span style="font-family:'Times New Roman'; font-size:11pt">SaBTO</span><span style="font-family:'Times New Roman'; font-size:11pt">. Bacterial contamination of blood components occurs at a very low rate too, and recent risk reduction measures and the introduction of bacterial screening of platelets have further minimised the risk of this occurring. </span></li></ol><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="7" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:150%; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Significantly, according to the 2011 Serious Hazards of Transfusion (SHOT) organisation’s Annual Report</span><a name="_ftnref2"></a><a href="#_ftn2">[2]</a><span style="font-family:'Times New Roman'; font-size:11pt">, 2010 was the first year in which there have been no confirmed cases of transfusion-transmitted infection, from any source including bacterial contamination.</span></li></ol><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="8" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:150%; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Furthermore, the UK Blood Services’ Standing Advisory Committee on Transfusion Transmitted Infection (SACTTI)</span><a name="_ftnref3"></a><a href="#_ftn3">[3]</a><span style="font-family:'Times New Roman'; font-size:11pt"> is alerted to any new infectious threats to the UK blood supply through a wide range </span><span style="font-family:'Times New Roman'; font-size:11pt">of reporting mechanisms, and will commission risk assessments where necessary to inform decisions on whether action should be taken to protect the safety of the blood supply. </span></li></ol><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="9" type="1" style="margin:0pt; padding-left:0pt"><li style="color:#222222; font-family:'Times New Roman'; font-size:11pt; line-height:150%; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="color:#000000; font-family:'Times New Roman'; font-size:11pt">As we say, </span><span style="color:#000000; font-family:'Times New Roman'; font-size:11pt">the high standards governing who can or cannot donate blood does cross-over to the regulation of the blood safety in general. </span><span style="color:#000000; font-family:'Times New Roman'; font-size:11pt">Risk assessments are provided to the Joint Professional Advisory Committee (JPAC) of the UK Blood Services and the National Institute for Biological Standards and Controls (NIBSC). These assessments are important, and will continue to be so, as they have possible implications for blood safety in areas such as tissue services and organ transplantation. Recent risk assessments in </span><span style="color:#222222; font-family:'Times New Roman'; font-size:11pt">Variant </span><span style="color:#000000; font-family:'Times New Roman'; font-size:11pt">Creutzfeldt-Jakob Disease</span><span style="color:#222222; font-family:'Times New Roman'; font-size:11pt"> (</span><span style="color:#000000; font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="color:#222222; font-family:'Times New Roman'; font-size:11pt">), this Committee’s inquiries concern, are an example of this.</span></li></ol><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="10" type="1" style="margin:0pt; padding-left:0pt"><li style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt; line-height:150%; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">However, we also want to bring to the Committee’s attention other risks recently identified by Arms-Length Bodies, such as </span><span style="color:#0d0d0d; font-family:'Times New Roman'; font-size:11pt">SaBTO</span><span style="color:#0d0d0d; font-family:'Times New Roman'; font-size:11pt">, such as emerging pathogens.</span><span style="font-family:'Times New Roman'; font-size:11pt"> Indeed, as the Committee may be aware, in a </span><span style="font-family:'Times New Roman'; font-size:11pt">SaBTO</span><span style="font-family:'Times New Roman'; font-size:11pt"> meeting from March, 2012, officials discussed the West Nile virus during their meeting and its continued threat to the safety and security of the UK blood supply. In order to combat this threat from emerging pathogens, </span><span style="font-family:'Times New Roman'; font-size:11pt">SaBTO</span><span style="font-family:'Times New Roman'; font-size:11pt"> subsequently recommended that pathogen reduction technology forms part of their Work Plan for 2012-2013</span><a name="_ftnref4"></a><a href="#_ftn4">[4]</a><span style="font-family:'Times New Roman'; font-size:11pt"> and has now formed a Working Group on the issue. Such technology could go a long way in reducing this threat.      </span></li><li style="color:#0d0d0d; font-family:'Times New Roman'; font-size:11pt; line-height:150%; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="color:#0d0d0d; font-family:'Times New Roman'; font-size:11pt">Terumo BCT believes that this blood safety inquiry offers an opportunity to highlight that the increased use of donor deferrals due to the threat of emerging pathogens, such as WNV, has been a major strand of NHSBT policy protecting the UK blood supply in recent years. However, each new outbreak or emergence of a blood borne pathogen and the subsequent use of donor deferrals by the NHSBT means that the potential pool of UK donors could be further reduced in time. As such, it could be said that the NHSBT strategy works for now but perhaps not in the future if there were new and widespread outbreaks of blood borne pathogens e.g. Hepatitis E.</span></li></ol><p style="background-color:#ffffff; font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="12" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:150%; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">To conclude, there are emerging threats to blood safety that are not always risk assessed and which could change the current threat landscape in the UK in this area. These threats require greater precautions to further reduce risks and the introduction of additional blood safety technology, such as pathogen reduction technology, to get as close to a zero tolerance risk approach as possible. </span></li></ol><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Is the Government and its scientific advisory structure sufficiently responsive to the threat posed by emerging diseases being transmitted through blood and blood products, tissues and organs?</span></p><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="13" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:150%; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The threats to the safety and security of the UK blood supply that require greater precautions, such as the emerging pathogens mentioned above, are partly reflected in a UK Government document from the Department for Environment, Food and Rural Affairs (DEFRA). Last year DEFRA published its Climate Change Risk Assessment (CCRA) for 2012. </span></li></ol><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="14" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:150%; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The publication draws together and interprets the evidence gathered by the Climate Change Risk Assessment panel regarding current and future threats for the UK posed by the impacts of climate up to the year 2100. It was written on a cross-Departmental basis and consequently draws upon the expertise from the Department of Health as well as the devolved administrations on the health threats from climate change, including higher disease prevalence. This directly impacts upon UK blood safety and highly relevant to this Committee’s inquiry on blood, tissue and organ screening. </span></li></ol><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="15" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:150%; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The publication of the CCRA is intended to inform policy-makers and other interested parties of the nature of the risks posed by climate change, the extent that the risks are currently understood (including the scale and time of onset of individual risks where possible), and the issues that influence the overall risk landscape for the UK as a whole. </span></li></ol><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="16" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:150%; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Indeed, the UK Climate Change Act 2008 makes the UK the first country in the world to have a legally binding, long-term framework to cut carbon emissions and the CCRA is the first such assessment resulting from the passing into law of this Act</span><a name="_ftnref5"></a><a href="#_ftn5">[5]</a><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li></ol><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="17" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:150%; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">As the CCRA says in the section on vector, water and food borne diseases, vector reproduction, parasite development and bite frequency generally rise with temperature. Therefore, West Nile virus, Malaria, tick-borne Encephalitis, and Dengue fever are very likely to become increasingly widespread in certain parts of the world due to projected rises in temperatures, something that the 2007 United Nations Intergovernmental Panel on Climate Change (IPCC) Report also points out. This is something that the </span><span style="font-family:'Times New Roman'; font-size:11pt">Committee should be aware of and something that the UK Government and its scientific advisory structure should closely monitor and be sufficiently responsive to in the future. </span></li></ol><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="18" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:150%; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The climate change threats outlined in the UK CCRA from 2012 involve different vectors that transport diseases such as West Nile virus </span><span style="font-family:'Times New Roman'; font-size:11pt">malaria, tick-borne encephalitis, and dengue fever. This is because v</span><span style="font-family:'Times New Roman'; font-size:11pt">ector-borne diseases rely upon organisms, named vectors, such as mosquitoes, ticks or sand flies that have an active role in the transmission of a pathogen from one host to the other, a development important for UK’s scientific advisory structure to be aware of in terms of blood safety in that humans are carriers of such diseases. </span></li></ol><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="19" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:150%; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Access to the latest blood safety technology is also of paramount importance in the response to these threats. Indeed, pathogen reduction technology and automated red cell exchange transfusion should be considered as part of the response.</span></li></ol><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="20" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:150%; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Indeed, pathogen reduction technology has been developed since the 2002 EU Blood Directive was adopted by Member States and it is a technology that significantly reduces the risk to patients of being infected with emerging and unknown pathogens. </span><span style="font-family:'Times New Roman'; font-size:11pt">Terumo BCT wishes to point out that the EU Blood Directive 2002 recommends that pathogen reduction technology should be adopted in EU Member States, which it subsequently has been and with a good track record of use too. </span></li></ol><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="21" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:150%; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Terumo BCT believes that the last 25 years have seen great strides in protecting recipients of blood transfusions and blood component derived treatments from the most dangerous blood borne diseases, such as </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt">, hepatitis and HIV. We all need to ensure that we keep it that way.</span></li></ol><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:150%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">January 2014</span></p><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p></div><hr style="width:33%; height:1px; text-align:left" /><h2 style="font-size:18pt; line-height:150%; margin:0pt 0pt 10pt; text-align:justify"><a name="_ftn1"></a><a href="#_ftnref1">[1]</a><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:normal">  The Advisory Committee on the Safety of Blood, Tissues and Organs (</span><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:normal">SaBTO</span><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:normal">), main website is: </span><a href="http://www.dh.gov.uk/ab/SaBTO/index.htm"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:10pt; font-weight:normal; text-decoration:underline">http://www.dh.gov.uk/ab/SaBTO/index.htm</span></a><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:normal">.</span></h2><p style="font-size:10pt; line-height:150%; margin:0pt 0pt 10pt; text-align:justify"><a name="_ftn2"></a><a href="#_ftnref2">[2]</a><span style="font-family:'Times New Roman'; font-size:10pt"> </span><span style="font-family:'Times New Roman'; font-size:10pt">Serious Hazards of Transfusion Report and Summary, website address:    </span><a href="http://www.shotuk.org/shot-reports/report-and-summary-2010-2/"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:10pt; text-decoration:underline">http://www.shotuk.org/shot-reports/report-and-summary-2010-2/</span></a><span style="font-family:'Times New Roman'; font-size:10pt">.</span></p><p style="font-size:10pt; line-height:150%; margin:0pt 0pt 10pt; text-align:justify"><a name="_ftn3"></a><a href="#_ftnref3">[3]</a><span style="font-family:'Times New Roman'; font-size:10pt"> </span><span style="font-family:'Times New Roman'; font-size:10pt">More information on the Standing Advisory Committee on Transfusion Transmitted Infection (SACTTI), go to the NHS Blood and Transplant website: </span><a href="http://www.nhsbt.nhs.uk/index.asp"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:10pt; text-decoration:underline">http://www.nhsbt.nhs.uk/index.asp</span></a><span style="font-family:'Times New Roman'; font-size:10pt">.</span></p><p style="font-size:12pt; line-height:150%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Minion Pro'; font-size:12pt">&#xa0;</span></p><p style="font-size:10pt; line-height:150%; margin:0pt 0pt 10pt; text-align:justify"><a name="_ftn4"></a><a href="#_ftnref4">[4]</a><span style="font-family:'Times New Roman'; font-size:10pt"> </span><span style="font-family:'Times New Roman'; font-size:10pt">The Advisory Committee on the Safety of Blood, Tissues and Organs (SaBTO) Work Plan for 2012-13 can be found here: </span><a href="https://www.wp.dh.gov.uk/transparency/files/2012/04/SaBTO%E2%80%99s-Work-programme-PDF23K.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:10pt; text-decoration:underline">https://www.wp.dh.gov.uk/transparency/files/2012/04/SaBTO%E2%80%99s-Work-programme-PDF23K.pdf</span></a><span style="font-family:'Times New Roman'; font-size:10pt">.</span></p><p style="font-size:10pt; line-height:150%; margin:0pt 0pt 10pt; text-align:justify"><a name="_ftn5"></a><a href="#_ftnref5">[5]</a><span style="font-family:'Times New Roman'; font-size:10pt"> The Climate Change (Scotland) Act 2009 provides a similar framework in Scotland.  </span></p></body></html>